More on what I’d like to call “therapeutic distress signals”. Like NPWT, which works on skin matrices, could Ilizarov, properly used, stimulate angiogenesis at a distance?
Even more data supporting a potential advance in diabetic wound healing, researchers have uncovered the mechanisms behind bone transport’s (BT) effectiveness in treating severe diabetic foot ulcers (DFUs). The study, conducted by Jing Xie et al. and published in Cell Reports Medicine, reveals how BT induces the release of small extracellular vesicles (sEVs) and antioxidant proteins that possess multi-tissue regenerative potential, offering promising therapeutic avenues for diabetic wound healing.
The Challenge of Diabetic Foot Ulcers
DFUs are a prevalent and severe complication of diabetes, affecting approximately 34% of diabetic patients and often leading to amputations. Current treatments focus on local wound care and optimized metabolic control but often result in high recurrence rates and eventual amputations. There is an urgent need for more specific and effective treatments for DFUs.
Bone Transport: A Mechanistic Insight
The Ilizarov bone transport (BT) technique, originally developed for orthopedic conditions, has been adapted to treat severe DFUs. This method, known as tibial cortex transverse distraction (TCTD), has shown a high limb salvage rate and a low recurrence rate in clinical practice. However, the underlying mechanisms of its efficacy were not well understood until now.
Xie and colleagues demonstrate that during BT, sEVs enriched with microRNAs (miRNAs) and antioxidant proteins are released. These sEVs accumulate in diabetic wounds, promoting tissue regeneration by enhancing neovascularization, fibroblast migration, and nerve fiber regeneration. One key miRNA identified is miR-494-3p, which plays a crucial role in these regenerative processes.
Experimental Findings
The researchers conducted both in vitro and in vivo experiments to elucidate the role of BT-released sEVs and antioxidants:
- In Rats: BT significantly accelerated wound healing in diabetic rats, evidenced by faster wound closure, increased neovascularization, and enhanced fibroblast and nerve bundle presence in the regenerated skin.
- In Humans: Plasma from DFU patients treated with BT promoted angiogenesis and cell migration in cultured human cells, underscoring the therapeutic potential of BT-induced factors.
Moreover, the study explored the therapeutic potential of ginsenoside Rg1, a compound that upregulates miR-494-3p. A randomized controlled trial confirmed that oral administration of Rg1 and reduced glutathione (GSH) significantly accelerated healing in patients with refractory DFUs.
A Promising Therapeutic Strategy
The findings suggest that the combination of BT-derived sEVs, miR-494-3p, and antioxidants could be a potent strategy for promoting diabetic wound healing. While BT itself is not suitable for all patients due to its surgical nature, the non-surgical approach of administering Rg1 and GSH offers a promising alternative.
Future Directions
Further research is needed to fully understand the molecular mechanisms at play and to optimize these therapeutic strategies. Large-scale clinical trials are warranted to validate the efficacy and safety of Rg1 and GSH in diverse patient populations. This potential advance in diabetic wound care holds promise for improving the quality of life for millions of diabetic patients worldwide.
For more detailed information, refer to the full study by Jing Xie et al. in Cell Reports Medicine. Link to manuscript.
Leave a Reply